Involving Dehydrogenase Patents (Class 435/26)
-
Publication number: 20130052675Abstract: The present invention relates to a testing system for assessing hypoxia induced cellular damage in a mammal including human, comprising a disposable device having a sample inlet and a collection chamber separated by a separation device wherein the collection chamber is connected to at least two, a first and a second, visible detection compartments, whereof at least one is arranged with chemical means for direct visual detection, said first detection compartment being arranged to determine whether level of hemoglobin (Hb) in a sample of body fluid taken from said mammal exceeds a predetermined threshold value, and said second detection compartment being arranged to evaluate level of total amount of lactate dehydrogenase (LDH) in said sample.Type: ApplicationFiled: September 30, 2010Publication date: February 28, 2013Applicant: CALMARK SWEDEN AKTIEBOLAGInventors: Mathias Karlsson, Sofia Hiort af Ornäs
-
Publication number: 20130052640Abstract: Clostridium difficile disease involves a range of clinical presentations ranging from carrier status with other causes of symptoms to mild and self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on the presence and then the severity of disease. Patients that are carriers may not receive treatment with concern of causing the disease. Mild to moderate cases may be treated with metronidazole while severe and relapsing cases are often treated with vancomycin or fidaxomicin. Current molecular assays are highly sensitive for detecting toxigenic C. difficile and cannot rule out carrier status. Utilization of a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin allows clinicians to differentiate between a carrier state and active state of C. difficile and allows for monitoring to evaluate the effectiveness of treatment.Type: ApplicationFiled: October 30, 2012Publication date: February 28, 2013Applicant: TECHLAB, INC.Inventor: TECHLAB, INC.
-
Patent number: 8383361Abstract: A polymer matrix that may coated on an electrode is created by co-crosslinking (1) an adduct of a polyaniline formed by templated oxidative polymerization on a polymer acid; (2) a water-soluble crosslinker; and (3) a redox enzyme. The polymer matrix may be hydrated, and the absorbed water may make it permeable to, for example, glucose. The polyaniline may be polyaniline itself or a substituted polyaniline; the water-soluble crosslinker may be poly(ethylene glycol)diglycidyl ether, and the redox enzyme may be glucose oxidase. The polymer matrix may be produced by co-crosslinking (1) an adduct of an electrically conductive polymer and a polymer acid; (2) a water-soluble crosslinker; and (3) a redox enzyme in a single step at an about neutral pH, curing by drying. After hydration, the crosslinked polymer matrix may form a 3-dimensional glucose-permeable bioelectrocatalyst, catalyzing the electrooxidation of glucose.Type: GrantFiled: December 14, 2011Date of Patent: February 26, 2013Assignee: Abbott Diabetes Care Inc.Inventors: Adam Heller, Benjamin J. Feldman, Nicolas Mano, Yueh-Lin Loo
-
Publication number: 20130029368Abstract: The present invention concerns methods and compositions for promoting a conversion in stem cells or cells derived therefrom from glycolysis to aerobic respiration and its associated pathways, including oxidative phosphorylation, the TCA cycle, fatty acid oxidation, and pyruvate decarboxylation, for example. In specific embodiments, certain media is employed to improve metabolic maturation of particular stem cell-derived cells, including human embryonic stem cells and human induced pluripotent stem cells, for example. Particular media comprises media without glucose or optionally without pyruvate, with fatty acids, with L-carnitine, with taurine, creatine, non-essential amino acids, L-glutamine, and with anti-oxidants or free-radical scavengers, for example.Type: ApplicationFiled: July 27, 2012Publication date: January 31, 2013Inventors: Steven Kattman, Chad Koonce, Natsuyo Aoyama, Jennifer Luebke-Wheeler, Brad Swanson
-
Publication number: 20130022969Abstract: The present invention relates to a strip for an improved lateral flow assay of a biological sample on a single plane and a lateral flow chromatography assay using a test device containing the same. The strip of the present invention consists of a single-pad, which can improve lateral flow assay by providing an easy and simple procedure and clear visual reading. The strip of the present invention is consisted of sample application (sample) zone and reactant-resultant zone where the reaction mixture is deposited (reactant) are all on a same plane. In addition, the present invention provides a chromatographic method wherein hemoglobin is separated from analyte by a differential chromatography on the solid phase. Any interference of detection of the result by hemoglobin is removed by the present invention. The present invention provides advantages including an easy and simple procedure with a quick and clear response.Type: ApplicationFiled: July 20, 2012Publication date: January 24, 2013Applicant: ACCESS BIO, INC.Inventors: Hyeon Suk KIM, Tae-Hee KOO, Young Ho CHOI
-
Patent number: 8354245Abstract: A lateral flow chromatographic assay format for the performance of rapid enzyme-driven assays is described. A combination of components necessary to elicit a specific enzyme reaction, which are either absent from the intended sample or insufficiently present therein to permit completion of the desired reaction, are predeposited as substrate in dry form together with ingredients necessary to produce a desired color upon occurrence of the desired reaction. The strip is equipped with a sample pad placed ahead of the substrate deposit in the flowstream, to which liquid sample is applied. The sample flows from the sample pad into the substrate zone where it immediately reconstitutes the dried ingredients while also intimately mixing with them and reacting with them at the fluid front. The fluid front moves rapidly into the final “read zone” wherein the color developed is read against predetermined color standards for the desired reaction. Pretreatment pads for the sample, as needed, (e.g.Type: GrantFiled: September 16, 2008Date of Patent: January 15, 2013Assignee: Alere Scarborough, Inc.Inventors: Roger N. Piasio, Nathan Turner
-
Publication number: 20130011871Abstract: In one non-limiting aspect, sterilizable reagent materials for diagnostic elements are provided. In other aspects, sterilized diagnostic elements and techniques for the production of the same are disclosed. In one embodiment, a sterilized diagnostic element includes a chemical detection reagent including at least one component that is sensitive to ionizing radiation. The sterilized diagnostic element is also mediator-free and the at least one component sensitive to ionizing radiation is present in a functional form in a proportion of ? 80% based on the total amount of the respective component in the diagnostic element before sterilization. In certain aspects, the at least one component sensitive to ionizing radiation includes one or both of an enzyme and a coenzyme. Other aspects include, but are not limited to, unique methods, techniques, products, systems and devices involving sterilizable reagent materials or sterilized diagnostic elements.Type: ApplicationFiled: June 11, 2012Publication date: January 10, 2013Inventors: Carina Horn, Nelli Steinke
-
Patent number: 8343726Abstract: The present invention provides assays and devices for detection of substances in liquid samples. The assays and devices utilize passive diffusion between a porous material and a porous membrane containing a specific binding pair member to enable detection of the substance of interest.Type: GrantFiled: November 23, 2005Date of Patent: January 1, 2013Assignee: Techlab, Inc.Inventors: James H. Boone, David M. Lyerly, Tracy D. Wilkins
-
Publication number: 20120295295Abstract: Methods of evaluating molecular isomers of branched-chain amino acids are featured. The methods can include: derivatizing one or more molecular isomers of branched-chain amino acids in a sample comprising a branched-chain amino acid labeled with one or more heavy atoms as a first standard; adding, to the sample, after derivatization, a nonderivatized or derivatized branched chain amino acid that is labeled with one or more heavy atoms, as a second standard; evaluating the sample using tandem mass spectrometry; and detecting peaks indicative of derivatized and nonderivatized forms of one or more branched-chain amino acids in the sample.Type: ApplicationFiled: July 16, 2012Publication date: November 22, 2012Applicant: PERKINELMER LAS, INC.Inventors: Blas Cerda, Alex Cherkasskiy, Yijun Li
-
Patent number: 8309329Abstract: By reacting inosinic acid (IMP) with a bacterium which has been modified so that IMP dehydrogenase activity and 5?-guanylic acid (GMP) synthetase activity are enhanced, GMP is produced.Type: GrantFiled: August 24, 2010Date of Patent: November 13, 2012Assignee: Ajinomoto Co., Inc.Inventors: Takayuki Asahara, Hiroaki Fukada, Kiyoshi Matsuno
-
Publication number: 20120282184Abstract: A method for the prevention or treatment of a condition selected from type 2 diabetes, obesity and metabolic syndrome comprising activating a GITRL pathway. Methods for screening for substances to treat these conditions, diagnosing or predicting these conditions and selecting and monitoring therapies.Type: ApplicationFiled: October 29, 2010Publication date: November 8, 2012Applicant: ISIS INNOVATION LTDInventors: Herman Waldmann, Kathleen Nolan, Lynn Poulton
-
Publication number: 20120276565Abstract: Methods for stabilizing an enzyme by storing the enzyme in the presence of a stabilized coenzyme are disclosed. In addition, an enzyme stabilized with a stabilized coenzyme as well as the use thereof in test elements for detecting analytes are also disclosed. Other aspects include unique compositions, methods, techniques, systems and devices involving enzyme stabilization.Type: ApplicationFiled: February 20, 2012Publication date: November 1, 2012Inventors: Wolfgang Roedel, Carina Horn, Nelli Steinke, Nadine Bucci, Thomas Meier, Rainer Schmuck, Rolf Nagel, Dieter Heindl
-
Patent number: 8288119Abstract: Human PGD genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of PGD are provided.Type: GrantFiled: June 20, 2005Date of Patent: October 16, 2012Assignee: Exelixis, Inc.Inventors: Chunyan Song, Michael Martin Ollmann, Lynn Margaret Bjerke
-
Publication number: 20120252047Abstract: A latent fluorophore is derived from salicylic acid, and containing a fluorogenic group and a moiety represented by formula I wherein the fluorogenic group is directly linked to the moiety of formula I or indirectly linked thereto via a linkage structure. In addition, a method of preparing a latent fluorophore, a method of using the same and a kit containing the same are also introduced.Type: ApplicationFiled: March 30, 2011Publication date: October 4, 2012Applicant: NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGYInventor: Sheng-Tung HUANG
-
Patent number: 8277636Abstract: The present invention relates to a glucose sensor (2) including an electrode (32) which includes a conductive component and glucose dehydrogenase immobilized to the conductive component. As the glucose dehydrogenase, use is made of a protein complex including a catalytic activity subunit which has glucose dehydrogenase activity, and an electron mediator subunit for supplying an electron donated from the catalytic activity subunit to the conductive component. Preferably, the glucose sensor (2) is designed to continuously measure the glucose level or successively measure the glucose level a plurality of times.Type: GrantFiled: February 17, 2009Date of Patent: October 2, 2012Inventor: Koji Sode
-
Publication number: 20120244567Abstract: Methods of culturing embryonic stem cells in a format suitable for high-throughput screening (HTS) are provided. In addition compounds that show differential cytotoxic/protective activity on embryonic stem cells (ESCs) and neurological stem cells (NSCs) are provided.Type: ApplicationFiled: September 3, 2010Publication date: September 27, 2012Applicant: BUCK INSTITUTE FOR RESEARCH ON AGINGInventor: Xianmin Zeng
-
Publication number: 20120237473Abstract: The invention relates to pharmaceutical compositions comprising trophic factors, methods to decrease the degeneration of a retina, methods of treating ocular degenerative diseases and methods to select cells for transplantation.Type: ApplicationFiled: March 14, 2012Publication date: September 20, 2012Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Anton Kolomeyer, Ilene Sugino, Marco Zarbin
-
Publication number: 20120220661Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.Type: ApplicationFiled: July 26, 2010Publication date: August 30, 2012Applicant: Baylor College of MedicineInventor: Brendan Lee
-
METHODS FOR TREATING CONDITIONS MEDIATED BY THE INFLAMMATORY CYTOKINE CASCADE USING GAPDH INHIBITORS
Publication number: 20120219546Abstract: The present invention is directed to a method of treating a subject at risk for or having a condition mediated by an inflammatory cytokine cascade comprising administering to the subject an amount of a GAPDH inhibitor effective to treat the subject at risk for or having a condition mediated by an inflammatory cytokine cascade.Type: ApplicationFiled: August 17, 2010Publication date: August 30, 2012Applicant: The Feinstein Institute for Medical ResearchInventors: Kevin Tracey, William Parrish -
Publication number: 20120164671Abstract: Systems and methods are provided for monitoring a immunosuppressant drug level and renal function, hepatic function, or a combination thereof in a patient, comprising obtaining a small volume blood sample from the patient; determining the level of at least one immunosuppressant drug in the small volume blood sample and determining the level of a second immunosuppressant drug or analyzing the renal function, the hepatic function, or a combination thereof in the patient. In some embodiments, the immunosuppressant drug levels are determined using a liquid chromatography tandem mass spectrometry (LC-MS/MS) procedure. Also provided are kits for use in any of the systems and methods described herein.Type: ApplicationFiled: February 29, 2012Publication date: June 28, 2012Inventor: Pleasant Fite Hooper
-
Patent number: 8206944Abstract: A novel dry stick device construction for the determination of an analyte in a sample is provided. The device comprises: (i) optionally a solid support, (ii) at least one reagent pad comprising a reagent or a combination of reagents capable of reacting with the analyte, a derivative of said analyte or an indicator compound for said analyte to provide a detectable signal when in a moistened state, the at least one reagent pad providing a first environment for said reagent(s), said first environment permitting an improved storage stability of the reagent(s) and dry stick device when in a non-moistened state, and (iii) a regulating pad being in contact with the at least one reagent pad, the regulating pad creating a second environment for said reagent(s), when in a moistened state, said second environment permitting an increased rate of reaction between the analyte and the reagent.Type: GrantFiled: January 19, 2007Date of Patent: June 26, 2012Assignee: Lattec I/SInventor: Kim Clausen
-
Publication number: 20120142041Abstract: Compositions and methods for the measuring toxicity, antioxidant capacity, and oxidative stress are provided.Type: ApplicationFiled: May 14, 2010Publication date: June 7, 2012Inventor: Iraimoudi S. Ayene
-
Publication number: 20120142650Abstract: Methods of treating lung diseases comprising administering inducers of NAD(P)H:quinone oxidoreductase 1 (NQO1) are disclosed. Inducers of NQO1 include naphthoquinones such as ?-lapachone. Methods of predicting whether a subject with a lung disease will respond to treatment with a naphthoquinone are also described herein.Type: ApplicationFiled: December 7, 2011Publication date: June 7, 2012Inventors: John Hollingsworth, William Michael Foster, Erin Potts Kant, Zhuowei Li
-
Publication number: 20120129206Abstract: The present invention provides methods of identifying subjects that are suitable for high-dose cyclophosphamide treatment.Type: ApplicationFiled: September 22, 2011Publication date: May 24, 2012Applicants: Accentia Biopharmaceuticals, Inc., The Johns Hopkins UniversityInventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, JR., Susan Bonitz, Adam Kaplin, Carlos Santos
-
Patent number: 8183004Abstract: The present invention relates to the use of short-chain SRL alcohol dehydrogenase (DHRS4, SEQ ID NO: 1) and peptides thereof as humoral biomarkers for the diagnostic detection and prognosis of the course, and also monitoring the course and therapy of septic inflammations and infections.Type: GrantFiled: March 6, 2006Date of Patent: May 22, 2012Assignee: B.R.A.H.M.S GmbHInventors: Andreas Bergmann, Joachim Struck, Monika Uhlein
-
Publication number: 20120121515Abstract: Methods of treating and evaluating subjects having neoactive mutants are described herein.Type: ApplicationFiled: March 12, 2010Publication date: May 17, 2012Inventors: Lenny Dang, Valeria Fantin, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Francesco G. Salituro, Jeffrey O. Saunders, Shinsan Su, Katharine Yen
-
Patent number: 8178311Abstract: The present invention is intended to provide a method for simultaneously measuring cholesterol in low density lipoprotein and total cholesterol as test components in blood. Specifically, a method is used for simultaneously measuring cholesterol in low density lipoprotein and total cholesterol in a biological sample, whereby cholesterol in low density lipoprotein and total cholesterol in a biological sample are quantified with a single measurement.Type: GrantFiled: February 9, 2009Date of Patent: May 15, 2012Assignee: Denka Seiken Co., Ltd.Inventor: Hiroshi Matsui
-
Publication number: 20120094321Abstract: Disclosed is a method for measuring a dehydrogenase or a substrate for the dehydrogenase contained in a sample, wherein both thio-NAD or thio-NADP and NAD or NADP are used as coenzymes. The method enables the measurement on the basis of absorbance values obtained in a visible region, and also enables the accurate measurement of a dehydrogenase or a substrate for the dehydrogenase which is contained in a sample at a high concentration.Type: ApplicationFiled: June 21, 2010Publication date: April 19, 2012Inventors: Kenta Noda, Yashiro Sato, Ryo Kojima
-
Publication number: 20120094320Abstract: A protein comprising an amino acid sequence having at least one mutation selected from a Gly-4 to Ala mutation, a Glu-6 to His mutation, a Ser-14 to Thr mutation, an Ala-37 to Thr or Arg mutation, a Pro-50 to Gln mutation, a Glu-67 to Gly mutation, an Asp-80 to Tyr mutation, a Val-93 to Met mutation, an Arg-156 to Pro mutation, a Leu-164 to Met mutation, an Asn-202 to Asp mutation, a Thr-235 to Ala mutation, an Asn-348 to Tyr mutation, a Gly-362 to Arg mutation and a Val-473 to Ala mutation in the amino acid sequence depicted in SEQ II NO:4. (2) A thermostable protein which comprises an amino acid sequence derived from the amino acid sequence having at least one variation described in (1) and having 1,5-anhydroglucitol dehydrogenase activity. These proteins act specifically on 1,5-anhydroglucitol (1,5-AG), have thermal stability and exhibit excellent storage stability.Type: ApplicationFiled: June 18, 2009Publication date: April 19, 2012Applicant: NIPPON KAYAKU KABUSHIKI KAISHAInventors: Hideki Yoshioka, Shuhei Tsukamoto, Minoru Masuda, Reiko Machida, Yoshihiko Umegae, Masahiko Yabuuchi
-
Publication number: 20120058992Abstract: The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, the invention relates to combined therapies that modulate angiogenesis for treating said disease.Type: ApplicationFiled: October 29, 2010Publication date: March 8, 2012Applicant: PHARNEXTInventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Oxana Guerassimenko, Esther Graudens
-
Publication number: 20120052520Abstract: Methods to determine the concentration of gamma-hydroxy butyric acid (GHB) in a sample as well as compositions and a kit suitable for carrying out said methods. Also, the use of the methods for application on a microtiter plate or an auto-analyzer.Type: ApplicationFiled: April 23, 2010Publication date: March 1, 2012Applicant: BUHLMANN LABORATORIES AGInventors: Lara Hasan, Michel-Angelo Sciotti, Thomas Jermann, Jakob Matthias Weber, Daniel Gygax, André Scholer
-
Publication number: 20120045476Abstract: The present invention provides live, attenuated Mycoplasma bacteria that exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type Mycoplasma bacterium of the same species. Also provided are vaccines and vaccination methods involving the use of the live, attenuated Mycoplasma bacteria, and methods for making live attenuated Mycoplasma bacteria.Type: ApplicationFiled: October 28, 2011Publication date: February 23, 2012Applicant: Wyeth LLCInventors: Mahesh KUMAR, Muhammad Ayub Khan
-
Publication number: 20120040362Abstract: This invention relates to hematopoietic precursors derived from human embryonic stem cells. In the culture of differentiated cells from human ES cells, the fully committed hematopoietic precursors are CD34+ and CD43+ but not CD45+. If the cells are cultured until they express CD45, then the cells lose the ability to produce differentiated cells of the lymphoid lineages.Type: ApplicationFiled: July 29, 2011Publication date: February 16, 2012Inventors: Igor I. Slukvin, Maksym A. Vodyanyk, James A. Thomson
-
Publication number: 20120040386Abstract: There is proposed a diagnostic test element for detecting an analyte in a sample of a body fluid, more particularly in whole blood. The diagnostic test element comprises at least one test field having at least one detection reagent, wherein the detection reagent is set up to pass through at least one detectable change in the presence of the analyte, more particularly an optical change. The test field has at least one detection layer which comprises the detection reagent and which comprises particles. At least 90% of all particles of the detection layer have an actual particle size of less than 10 micrometers.Type: ApplicationFiled: May 3, 2011Publication date: February 16, 2012Inventors: Wolfgang-Reinhold Knappe, Bernd Hiller, Ursula Lehr, Volker Zimmer, Wolfgang Petrich, Luis David Bedon-Gomez
-
Publication number: 20120034210Abstract: The present invention concerns a composition for potentiating formation of DISC (Death Inducing Signaling Complex) macro-complex and for inducing apoptotic signal mediated by death receptors in tumour cells comprising a therapeutically effective amount of an active agent selected among a hypocalcemia-inducing agent, a calcium channel inhibitor and a calcium chelator in association with a therapeutically effective amount of an anticancer agent inducing an apoptotic signal via death receptors Fas, TNF-R1, DR4 and/or DR5.Type: ApplicationFiled: December 4, 2009Publication date: February 9, 2012Applicants: INSTITUT BERGONIE, UNIVERSITE VICTOR SEGALEN BORDEAUX 2Inventors: Pierre Vacher, Patrick Legembre, Laurence Bepoldin, Pierre Soubeyran, Anne-Marie Vacher, Benjamin Chaigne-Delalande
-
Publication number: 20120028287Abstract: The present disclosure provides a crystal structure of aldehyde dehydrogenase (ALDH) with a modulator of ALDH bound thereto. The present disclosure provides a computer readable medium comprising atomic coordinates for an ALDH polypeptide and a modulator bound to a site within the polypeptide. A method is also provided. In general terms, the method comprises computationally identifying a compound that binds to an ALDH polypeptide, using the atomic coordinates.Type: ApplicationFiled: October 10, 2011Publication date: February 2, 2012Inventors: Che-Hong CHEN, Daria MOCHLY-ROSEN, Thomas D. HURLEY
-
Publication number: 20120028282Abstract: A biosensor system can comprise a sensor chip and a measurement device. The sensor chip comprises a capillary and electrodes disposed within the capillary. The height of the capillary is set to be less than the maximum value of the sum of the diffusion distance of an electron-transfer mediator and the diffusion distance of an analyte at the upper limit of the measurement guaranteed temperature of the biosensor system. The measurement device applies an open circuit voltage, a voltage that is lower than during concentration measurement, or the like to the electrodes of the sensor chip.Type: ApplicationFiled: May 20, 2010Publication date: February 2, 2012Inventor: Motonori Uchiyama
-
Publication number: 20120010248Abstract: The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2.Type: ApplicationFiled: August 22, 2011Publication date: January 12, 2012Inventors: Daria Mochly-Rosen, Che-Hong Chen, Xiaohu Ouyang
-
Publication number: 20120003661Abstract: Methods and devices are provided for the rapid and specific detection of target microorganisms, cells, and the like. In one embodiment, the methods involve contacting a target microorganism (e.g., in a sample) with a permeabilization reagent that selectively permeabilizes or lyses the microorganism; contacting the selectively permeabilized microorganism with a detection reagent that is taken into the selectively permeabilized organism or that contacts metabolites or enzymes released by the selectively permeabilized microorganism, where the detection reagent produces a signal in the presence of said metabolites or enzymes; and detecting a signal produced by the detection reagent in the presence of the metabolites or enzymes wherein the strength of the signal indicates the presence and/or amount of the target microorganism in the sample.Type: ApplicationFiled: June 27, 2011Publication date: January 5, 2012Applicant: C3 JIAN, INC.Inventors: Randal H. Eckert, Chris Kaplan, Jian He, Daniel K. Yarbrough, Maxwell Anderson, Jee-Hyun Sim
-
Publication number: 20120003156Abstract: The invention provides compositions for the diagnosis or treatment of neoplasias, including lymphomas, leukemias, brain cancers (e. glioblastomas, medulloblastomas), breast cancer, colon cancer, and pancreatic cancer, and methods of use therefor.Type: ApplicationFiled: July 1, 2009Publication date: January 5, 2012Applicant: The Johns Hopkins UniversityInventors: Chi V. Dang, Quy H. Le, Ramani Dinavahi
-
Publication number: 20110321197Abstract: A method for producing a plant with increased yield as compared to a corresponding wild type plant whereby the method comprises at least the following step: increasing or generating in a plant or a part thereof one or more activities selected from the group consisting of 17.6 kDa class I heat shock protein, 26.Type: ApplicationFiled: October 2, 2009Publication date: December 29, 2011Applicant: BASF Plant Science GmbHInventors: Hardy Schön, Oliver Thimm, Gerhard Ritte, Oliver Bläsing, Koen Bruynseels, Yves Hatzfeld, Valerie Frankard, Ana Isabel Sanz Molinero, Christophe Reuzeau, Steven Vandenabeele
-
Publication number: 20110312001Abstract: The invention generally features methods for providing engineered pluripotent stem cells that can be used to study biological response and pathways, including differentiation and drug effects. For example, these cells are provided comprising two or more exogenous expression cassettes including a selectable or screenable marker under the control of different condition-responsive regulatory elements, such as differentiation-responsive promoters or regulatory element of a receptor, drug target, drug metabolizing enzyme or signaling pathway gene. Also provided are sets of stem cell lines each comprising a different exogenous expression cassette including a selectable or screenable marker under the control of a different condition-responsive regulatory element.Type: ApplicationFiled: June 15, 2011Publication date: December 22, 2011Inventors: Emile Nuwaysir, Chris Kendrick-Parker, Nicholas Seay
-
Patent number: 8080385Abstract: A polymer matrix that may coated on an electrode is created by co-crosslinking (1) an adduct of a polyaniline formed by templated oxidative polymerization on a polymer acid; (2) a water-soluble crosslinker; and (3) a redox enzyme. The polymer matrix may be hydrated, and the absorbed water may make it permeable to, for example, glucose. The polyaniline may be polyaniline itself or a substituted polyaniline; the water-soluble crosslinker may be poly(ethylene glycol) diglycidyl ether, and the redox enzyme may be glucose oxidase. The polymer matrix may be produced by co-crosslinking (1) an adduct of an electrically conductive polymer and a polymer acid; (2) a water-soluble crosslinker; and (3) a redox enzyme in a single step at an about neutral pH, curing by drying. After hydration, the crosslinked polymer matrix may form a 3-dimensional glucose-permeable bioelectrocatalyst, catalyzing the electrooxidation of glucose.Type: GrantFiled: May 2, 2008Date of Patent: December 20, 2011Assignee: Abbott Diabetes Care Inc.Inventors: Adam Heller, Benjamin J. Feldman, Nicolas Mano, Yueh-Lin Loo
-
Publication number: 20110306076Abstract: The present invention relates to cellobiose dehydrogenases (CDH) having glucose oxidation activity at a pH of 7.4 or above, modifications to modify the pH dependency of the enzymes activity, uses for these CDHs, in particular electrode sensors and electrochemical cells.Type: ApplicationFiled: February 26, 2010Publication date: December 15, 2011Inventors: Roland Ludwig, Dietmar Haltrich, Wolfgang Harreither, Lo Gorton
-
Publication number: 20110293525Abstract: Tumor stem cells can be obtained by culturing a tumor cell population, and exposing the cultured tumor cell population to free radicals. In certain embodiments, the free radical agent can be a nitric oxide (NO) donor. In one embodiment, the free radical agent can be Diethylenetriamine NONOate (DETA NONOate) or agents that constitutively increase cellular nitric oxide, such as phosphodiesterase inhibitors or L-arginine, or agents that increase NO synthase in the population. The methods can further include inducing stem cells present in the population to expand and/or inducing dedifferentiation of tumor cells into tumor stem cells. Additionally, the present invention provides methods of selecting stem cells from a tumor cell population.Type: ApplicationFiled: May 31, 2011Publication date: December 1, 2011Applicant: BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventor: James A. Radosevich
-
Publication number: 20110287461Abstract: The invention is directed to a novel enzymatic analytical membrane, a lateral flow enzymatic detection method, and analytical device incorporating same. The invention is useful for rapidly enzymatically determining the presence of one or more analytes in small volumes of sample. The invention provides an enzymatic analytical membrane for detecting the presence of one or more small-molecule analytes in a biological sample where the membrane comprises a receiving zone; a separation zone and a signal zone, at least one of the zones comprising one or more enzymes for converting the analytes into a form detectable by reaction with a chromogenic agent present in the signal zone and wherein the membrane horizontally receives sample at the receiving zone, and the sample continues via lateral flow through the receiving zone, separation zone and signal zone where a visible color change is formed indicating the presence of the analyte.Type: ApplicationFiled: May 26, 2009Publication date: November 24, 2011Applicant: ZBX CORPORATIONInventor: Qinwei Shi
-
Publication number: 20110287437Abstract: The likelihood that a compound will exhibit cardiotoxicity in vivo can be predicted using a model of in vitro assays performed on primary human cardiomyocytes.Type: ApplicationFiled: May 20, 2010Publication date: November 24, 2011Inventors: Hans Marcus Ludwig Bitter, Kyle Louis Kolaja, Preeti Dhawan, Hirdesh Uppal, Rama Rajaraja Varma
-
Publication number: 20110281287Abstract: A test strip or electrochemical sensor for measuring the amount of an analyte in a biological fluid, e.g. the glucose content of whole blood, includes a size self-limiting reagent formulation employing an enzyme system for reaction with the analyte, the reactive system mixed into a water-soluble swellable polymer matrix containing small water-insoluble particles having a nominal size of about 0.05 to 20 ?m, preferably about 1 to 10 ?m. The weight ratio of the water-insoluble particles to the water-soluble swellable polymer matrix is about 1/2 to 2/1. The reagent formulation is deposited onto a non-porous substrate to form a thin layer about 6-16 ?m thick, providing a rapid and stable response to application of a sample, while being insensitive to the amount of the sample.Type: ApplicationFiled: May 11, 2011Publication date: November 17, 2011Applicant: Bayer Healthcare LLCInventor: Karen L. Marfurt
-
Publication number: 20110262451Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of isovaleryl-coenzyme A dehydrogenase (IVD), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.Type: ApplicationFiled: May 7, 2009Publication date: October 27, 2011Inventors: Jérôme Aubert, Tony Minier, Valérie Trinquet, Michel Rivier
-
Publication number: 20110265197Abstract: The present invention provides methods of detecting cancer using biomarkers.Type: ApplicationFiled: July 16, 2009Publication date: October 27, 2011Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Ronald Depinho, Zhihu Ding, Lynda Chin